AstraZeneca said Friday that its recently approved breast cancer drug Etcamah failed a late-stage trial designed to support a ...
FDA approves Scholar Rock's Isembyld (apitegromab) for SMA after Indiana manufacturing hurdles; shares jump 10% premarket.
Definium Therapeutics' DT120 met endpoints in Phase 3 Panorama GAD trial, planning FDA submission for DT120 in GAD and MDD ...
As gene therapy manufacturing continues to mature, the focus is shifting. Most gene therapy developers begin this work ...
From Monday on, the Danish drugmaker will commonly be known as ‘Novo’ as part of a shift dubbed “The Novo Way,” according to a press release. The rebrand is meant to make the company ...
Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22 ...
Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now ...
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is ...
Anthropic posts a corporate development role for life sciences dealmaking, paying up to $600,000, as its biotech push and IPO ...
TwoStep raised a $62.5M Series A backed by Pfizer and Merck KGaA's venture arms to push its peptide-drug conjugate toward Phase 1 this year.
Compass psilocybin drug reports 13-pt reduction in depression score; Solstice debuts with $225M Series A; Luma unveils $410M ...
BridgeBio Oncology's stock drops 24% as it narrows BBO-8520 to 2L+ NSCLC, trimming its broader KRAS pipeline plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results